Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need. Basic science and clinical investigators across the world have been working on many new and old molecule formulations and combination strategies to improve outcomes in this disease. In this review, we discuss select promising novel agents in various stages of clinical development for patients with AML.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252053 | PMC |
| http://dx.doi.org/10.3390/cancers15112958 | DOI Listing |
Publication Analysis
Top Keywords
acute myeloid
8
myeloid leukemia
8
novel investigational
4
investigational agents
4
agents pathways
4
pathways influence
4
influence future
4
future management
4
management acute
4
leukemia acute
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!